IDH3A Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, designed to disrupt the IDH3A gene encoding the catalytic subunit of mitochondrial NAD-dependent isocitrate dehydrogenase. This loss-of-function model facilitates investigation of IDH3A’s role in the tricarboxylic acid (TCA) cycle without clonal selection bias. The polyclonal format provides a heterogeneous mixture of edited alleles, capturing the spectrum of gene disruption outcomes and enabling study of population-level metabolic adaptations. Researchers can thus probe immediate and compensatory responses to TCA cycle disruption in a genetically diverse cellular context.
The host HeLa cell line is an immortalized, HPV18-positive cervical adenocarcinoma model extensively used in cancer biology, virology, and metabolic research. These cells exhibit a high glycolytic rate and robust proliferative capacity, offering a well-characterized background for interrogating mitochondrial function in a cancer context. The immortalized phenotype ensures reproducible gene editing and culture scalability. In this model, IDH3A knockout dissects the specific contribution of the NAD-dependent isocitrate dehydrogenase complex to cellular energetics, redox homeostasis, and anabolic pathways, contextualizing TCA cycle perturbations within a prototypical human cancer cell line.
IDH3A encodes the catalytic ??-subunit of mitochondrial NAD-dependent isocitrate dehydrogenase, which catalyzes isocitrate to ??-ketoglutarate conversion coupled with NADH production. This TCA cycle enzyme is regulated by PGC-1??, NRF-1, NRF-2, ATP/ADP ratio, NAD+/NADH ratio, and Ca2+. It forms a complex with IDH3B and IDH3G as part of the TCA cycle metabolon. Downstream, reduced IDH3A activity lowers ??-ketoglutarate and NADH levels, attenuating cycle flux and impacting redox balance and amino acid metabolism. IDH3A sits among core TCA enzymes CS, ACO2, OGDH, SDH, and MDH2.
In HeLa cells, IDH3A knockout illuminates the dependency of cervical adenocarcinoma metabolism on mitochondrial respiration and anaplerotic pathways. Cancer cells frequently reprogram energy metabolism, and ablation of a core TCA enzyme provides a system to test metabolic vulnerabilities linked to proliferation, apoptosis, and therapeutic resistance. Because HeLa cells sustain high glycolytic flux, the knockout model can uncover adaptive shifts between glycolysis and residual mitochondrial activity, as well as alterations in metabolite signaling. Notably, reduced ??-ketoglutarate levels may impair ??-ketoglutarate-dependent dioxygenases involved in epigenetic modifications and hypoxia response, extending the model’s relevance to tumor biology and metabolic disease.
This IDH3A knockout polyclonal population enables metabolic flux analysis using Seahorse analyzers, NAD+/NADH ratio measurements, LC-MS-based metabolomic profiling, and cell proliferation/apoptosis assays. It supports validation of TCA cycle drug targets, modeling of leukoencephalopathy and other metabolic encephalopathies, and exploration of mitochondrial roles in cancer. Protein interaction studies involving IDH3B and IDH3G can be performed. Gene disruption is confirmed by Western blotting and RT-qPCR. For further information, contact Ascent Research.
